

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

A comparison of the effect of taurolidine and 4 % citrate(TauroLock™ - HEP500) and Heparin use in Port catheter on the function of catheter and prevention of catheter complications in children with malignancy

Protocol summary

Study aim

A comparison of the effect of taurolidine and 4 % citrate and Heparin use in Port catheter on the function of catheter and prevention of catheter complications in children with malignancy

Design

Sampling in this study is convenience sampling method. This clinical trial has a control group, with parallel groups, single-blinded, non-randomized, phase 3 on 72 patients.

Settings and conduct

Sampling is collected from patients referred to the Oncology Department of Ali Asghar Hospital in Tehran. All patients have Polysite (Vygon) single lumen catheters. Based on clinical needs, After each treatment cycle, the patient's port catheters are filled with a solution of about 5 cc of heparin varnish in the first group, and in the second group, a solution of 2.5 to 3 cc of Taurolock solution is used.

Participants/Inclusion and exclusion criteria

Inclusion criteria include: 1- Age between 1 month and 19 years 2- The need to have a port catheter for the purposes of chemotherapy for malignancies, not just transfusion of blood and blood products. 3-Informed consent Exclusion criteria: 1- Patients who are transferred to departments other than oncology 2- Patients who have hereditary coagulation disease. 3- Patients who have a non-tunneled Port catheter. 4- Patients who have hematological diseases without neutropenia (such as Diamond Blackfan anemia and sickle cell anemia).

Intervention groups

In the intervention group, which includes 38 patients, after each cycle of chemotherapy, the catheter port is filled with 5 cc of Taurolock solution. In the control group, which includes 38 patients, after the end of each chemotherapy, after washing the Port Catheter with

normal saline, they will be varnished with a sufficient amount of Heparin solution.

Main outcome variables

This study measures the function of the catheter during the 6 months. ; inflammatory markers: including IL-6, Total WBC, CRP

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20201107049296N4**

Registration date: **2023-10-22, 1402/07/30**

Registration timing: **registered_while_recruiting**

Last update: **2023-10-22, 1402/07/30**

Update count: **0**

Registration date

2023-10-22, 1402/07/30

Registrant information

Name

Aziz Eghbali

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2268 8027

Email address

eghbali.a@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-10-07, 1402/07/15

Expected recruitment end date

2024-01-30, 1402/11/10

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
A comparison of the effect of taurolidine and 4 % citrate(TauroLock™-HEP500) and Heparin use in Port catheter on the function of catheter and prevention of catheter complications in children with malignancy

Public title
Assessment of TauroLock™ in port catheter

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Children who have recently been diagnosed with malignancy requiring chemotherapy Children who need Port-a-Cath for treatment of malignancy, not only transfusion. Consent of patients' parents and implicit consent of children with decision-making capacity Children Aged between 1 month to 19 years
Exclusion criteria:
Having congenital coagulation disorder Having non-tunneled Port-a-Cath History of congenital hematologic disorders

Age
From **1 month** old to **19 years** old

Gender
Both

Phase
3

Groups that have been masked

- Outcome assessor
- Data analyser

Sample size
Target sample size: **72**

Randomization (investigator's opinion)
Randomized

Randomization description
For this study, we will use the stratified block randomization method to allocate patients into two groups, A and B, with a 1:1 ratio. The blocks will be of sizes 6 and 8 and will be stratified according to age. The age groups are 0-5 years, 5-9 years, 9-14 years, and 14-18 years. We will use www.sealedenvelope.com to provide the randomization. The information will be entered into the website in groups A and B, with a list length appropriate for the sample size and the previously mentioned stratification. The main researcher will receive the results once the allocation is complete.

Blinding (investigator's opinion)
Single blinded

Blinding description
In this study, blinding was done only for the outcome assessor, the third collaborator of the project who reviews the patients' tests and clinical data without

knowing the patient's allocation to a specific group. The Methodologist also analyses the data generally without knowing whether each data belongs to a specific group.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Iran University of Medical Sciences
Street address
Iran university of medical science., Next to Milad Tower., Hemmat Highway., Tehran
City
Tehran
Province
Tehran
Postal code
۱۴۴۹۶۱۴۵۳۵

Approval date
2023-10-07, 1402/07/15

Ethics committee reference number
IR.IUMS.REC.1402.598

Health conditions studied

1

Description of health condition studied
Drugs used in chemotherapy

ICD-10 code
Z51.1

ICD-10 code description
Chemotherapy session for neoplasm

Primary outcomes

1

Description
Serum Interleukin-6 level

Timepoint
Before intervention, 1 month after entering the study and 6 month after entering

Method of measurement
Patients' serologic examinations; the serum IL-6 level will be measured in pg/dl

2

Description

Duration of Port-a-Cath function

Timepoint

On the first medical contact and then every chemotherapy session or every month (whichever is earlier) up to 6 months.

Method of measurement

The number of days that the port catheter has had a diagnostic or therapeutic function so that blood and fluids can move in both directions.

Secondary outcomes

1

Description

Serum CRP level

Timepoint

At the beginning of the study the 1 month later and 6 months later

Method of measurement

Serum CRP level will be measured by serologic examinations.

Intervention groups

1

Description

Intervention group: All patients have a single-lumen Polysite(Vygon) catheter. Catheters are used for the purposes of chemotherapy and the transfer of blood and serum products and other drugs. A bio-occlusive adhesive is also placed at the exit of the catheter from the skin, which is changed every three days, and the area will be disinfected with a Povidone-iodine solution. Based on the patient's clinical needs, port catheters are used after each treatment cycle in the intervention group from 2.5 to 3 cc of Taurolock™ solution (Taurolidine 1.35%/sodium citrate 4% Taurolock™, Tauropharm, Waldbüttelburn, Germany).

Category

Treatment - Drugs

2

Description

Control group: In the control group, all patients have single-lumen Polysite (Vygon) catheters. The catheters are used after being placed subcutaneously by a pediatric surgeon under standard and identical conditions for the purposes of chemotherapy and the transfer of blood and serum products and other drugs. According to the patient's clinical needs, the port catheters are diluted with 5 cc of heparin lock solution (5000 IU heparin/0.2 ml) Darou Pakhsh, Tehran, Iran, diluted up to 100 IU heparin/ml with 0.9% sterile normal saline after each treatment cycle

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Tehran Ali Asghar Children's Hospital

Full name of responsible person

Aziz Eghbali

Street address

Ali Asghar Children's Hospital, Zafar St, Modares Hwy

City

Tehran

Province

Tehran

Postal code

۱۹۱۹۸۱۶۷۶۶

Phone

+98 21 2304 6413

Email

eghbali.a@iums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Reza Falak

Street address

Iran University of Medical Sciences, East Hemmat Expressway, Tehran

City

Tehran

Province

Tehran

Postal code

۱۴۳۹۶۱۴۵۳۵

Phone

+98 21 8670 3248

Email

falak.r@iums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

eghbali.a@iums.ac.ir

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Aziz Egbali

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Hematology

Street address

Ali Asghar Children's Hospital, Zafar St, Modares Hwy

City

Tehran

Province

Tehran

Postal code

۱۹۱۹۸۱۶۷۶۶

Phone

+98 21 2222 2041

Email

eghbali.a@iums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Aziz Egbali

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Hematology

Street address

Aliasghar children's hospital, Dastgerdi st., Zafar st.,

Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1919816766

Phone

+98 21 2268 8027

Fax**Email**

Person responsible for updating data

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Aziz Egbali

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

Aliasghar children's hospital, Dastgerdi st., Zafar st.,

Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1919816766

Phone

+98 21 2268 8027

Fax**Email**

eghbali.a@iums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available